A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
CA209655

To Learn More Call
201-510-0910

A Phase ½ Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB 24360) in Subjects with Selected Cancers

Type of Cancer
Unknown

Sponsor
Incyte

Protocol Number
24360-202:

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Type of Cancer
Myelodysplastic Syndrome

Sponsor
Janssen

Protocol Number
63935937MDS3001

To Learn More Call
201-510-0910

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anaemia and non-dialysis-dependent chronic kidney disease

Type of Cancer
Renal Cancer

Site
Bethesda

Protocol Number
P-MONOFER-CKD-04

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910